Although we provide strong evidence that HAT1 inhibition may suppress tumor growth, reverse drug resistance, and improve the prognosis of pancreatic cancer, there are currently no HAT1 small molecule inhibitors. Here, HAT1 is linked to familial pancreatic carcinoma.